JPS5782317A - Coronary sclerosis preventing and treating agent - Google Patents

Coronary sclerosis preventing and treating agent

Info

Publication number
JPS5782317A
JPS5782317A JP56147731A JP14773181A JPS5782317A JP S5782317 A JPS5782317 A JP S5782317A JP 56147731 A JP56147731 A JP 56147731A JP 14773181 A JP14773181 A JP 14773181A JP S5782317 A JPS5782317 A JP S5782317A
Authority
JP
Japan
Prior art keywords
preventing
treating agent
coronary sclerosis
coronary
sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP56147731A
Other languages
English (en)
Japanese (ja)
Inventor
Piitaa Richiyaadoson Buraian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of JPS5782317A publication Critical patent/JPS5782317A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP56147731A 1980-09-18 1981-09-17 Coronary sclerosis preventing and treating agent Pending JPS5782317A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8030228 1980-09-18

Publications (1)

Publication Number Publication Date
JPS5782317A true JPS5782317A (en) 1982-05-22

Family

ID=10516153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56147731A Pending JPS5782317A (en) 1980-09-18 1981-09-17 Coronary sclerosis preventing and treating agent

Country Status (5)

Country Link
JP (1) JPS5782317A (fr)
AU (1) AU7544281A (fr)
BE (1) BE890369A (fr)
IT (1) IT1210577B (fr)
PH (1) PH20494A (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554623A (en) * 1988-05-10 1996-09-10 Ergo Science Incorporated Method for the long term reduction of body fat stores, insulin resistance, hypersinsulinemia and hyperglycemia in vertebrates
US5679685A (en) * 1993-12-22 1997-10-21 Ergo Science, Incorporated Accelerated release composition containing bromocriptine

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8426922D0 (en) * 1984-10-24 1984-11-28 Sandoz Ltd Galenic formulation
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5006526A (en) * 1988-10-17 1991-04-09 Louisiana State University Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
CA2030174C (fr) * 1990-01-10 1996-12-24 Anthony H. Cincotta Procede pour la reduction a long terme des reserves lipidiques, de l'insulinoresistance, de l'hyperinsulinemie et de l'hypoglycemie chez les vertebres
US5565454A (en) * 1995-05-31 1996-10-15 Ergo Science, Incorporated Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554623A (en) * 1988-05-10 1996-09-10 Ergo Science Incorporated Method for the long term reduction of body fat stores, insulin resistance, hypersinsulinemia and hyperglycemia in vertebrates
US5635512A (en) * 1988-05-10 1997-06-03 Ergo Science Incorporated Method for modifying or resetting the prolactin rhythm of an insulin insensitive or diabetic animal or human
US5654313A (en) * 1988-05-10 1997-08-05 Ergo Science Incorporated Method for modifying or regulating the glucose metabolism of an animal or human subject
US5716957A (en) * 1988-05-10 1998-02-10 The Board Of Supervisors Of Louisiana State And Agricultural And Mechanical College Method for modifying and resetting the bloodstream prolactin levels of a human subject
US5719160A (en) * 1988-05-10 1998-02-17 The Board Of Supervisors Of Louisiana State And Agricultural And Mechanical College Method for modifying and regulating lipid metabolism
US5731312A (en) * 1988-05-10 1998-03-24 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5679685A (en) * 1993-12-22 1997-10-21 Ergo Science, Incorporated Accelerated release composition containing bromocriptine

Also Published As

Publication number Publication date
PH20494A (en) 1987-01-21
AU7544281A (en) 1982-03-25
IT8149328A0 (it) 1981-09-18
IT1210577B (it) 1989-09-14
BE890369A (fr) 1982-03-16

Similar Documents

Publication Publication Date Title
JPS5782313A (en) Powdery wound treating agent and manufacture
DE3160293D1 (en) Textile treating agent
DE3169631D1 (en) Soil treating agent
JPS5515444A (en) Prescribed substance for thrombosis prevention and remedy
JPS57133279A (en) Fiber treating agent
JPS5716099A (en) Coated bleaching agent and method
JPS57171768A (en) Fiber treating agent
JPS5716976A (en) Fiber treating agent
DE3162761D1 (en) Triazoloquinoxalin-4-ones and such oxaline-4-thiones
PH19156A (en) Dihydrocyclosporin d in the treatment of multiple sclerosis
GB2090529B (en) Thrombosis-prophylactic and curing agent
JPS5717661A (en) Removing agent and its manufacture
JPS5782317A (en) Coronary sclerosis preventing and treating agent
JPS5782320A (en) Immune t-system controlling agent and manufacture
DE3271010D1 (en) Surface treating agent
GB2070016B (en) 17-acyloxy-5-corticoids and 17-acyloxy-5-corticoids
JPS56127683A (en) Slag treating and recirculating method
JPS5741377A (en) Coating composition and method
JPS5739285A (en) Anti-stain treating agent
JPS56135417A (en) Wound treating method and composition
JPS56159364A (en) Fiber treating agent
JPS56148974A (en) Fiber treating agent
ZA811422B (en) Titration agent and method of using same
JPS54163897A (en) Betaalactamase inhibiting agent em4615 and method
JPS57192557A (en) Deodrant treatment agent